1. Home
  2. CCK vs EXAS Comparison

CCK vs EXAS Comparison

Compare CCK & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Crown Holdings Inc.

CCK

Crown Holdings Inc.

HOLD

Current Price

$98.43

Market Cap

11.2B

Sector

Industrials

ML Signal

HOLD

Logo Exact Sciences Corporation

EXAS

Exact Sciences Corporation

HOLD

Current Price

$101.08

Market Cap

11.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCK
EXAS
Founded
1906
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Containers/Packaging
Medical Specialities
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.2B
11.0B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CCK
EXAS
Price
$98.43
$101.08
Analyst Decision
Strong Buy
Buy
Analyst Count
14
20
Target Price
$118.57
$76.38
AVG Volume (30 Days)
2.1M
10.3M
Earning Date
10-20-2025
11-03-2025
Dividend Yield
1.06%
N/A
EPS Growth
888.69
N/A
EPS
8.10
N/A
Revenue
$12,141,000,000.00
$3,082,033,000.00
Revenue This Year
$4.78
$19.40
Revenue Next Year
$2.75
$13.51
P/E Ratio
$12.09
N/A
Revenue Growth
3.27
14.47
52 Week Low
$75.98
$38.81
52 Week High
$109.48
$101.87

Technical Indicators

Market Signals
Indicator
CCK
EXAS
Relative Strength Index (RSI) 52.92 89.74
Support Level $96.66 $100.98
Resistance Level $100.12 $101.43
Average True Range (ATR) 1.88 2.25
MACD 0.16 0.53
Stochastic Oscillator 67.91 97.74

Price Performance

Historical Comparison
CCK
EXAS

About CCK Crown Holdings Inc.

Crown Holdings is one of the world's largest producers of metal packaging. The company manufactures beverage cans, metal food cans, and closures as well as aerosol cans. With the purchase of Signode, the company also has a presence in a wide variety of protective transport packaging. Although it's headquartered in the United States, the vast majority of Crown's sales come from its operations in Europe, South America, and Southeast Asia.

About EXAS Exact Sciences Corporation

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

Share on Social Networks: